{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:20:47Z","timestamp":1782915647256,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.jaip.2016.03.008","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T19:49:29Z","timestamp":1461959369000},"page":"740-746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Adverse Drug Reactions Associated with Ceftaroline Use: A 2-Center Retrospective Cohort"],"prefix":"10.1016","volume":"4","author":[{"given":"Kimberly G.","family":"Blumenthal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"James L.","family":"Kuhlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana A.","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy A.","family":"Varughese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Kubiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleena","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica S.","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2016.03.008_bib1","first-page":"3","article-title":"Ceftaroline: a new cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA)","author":"Duplessis","year":"2011","journal-title":"Clin Med Rev Ther"},{"key":"10.1016\/j.jaip.2016.03.008_bib2","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1093\/cid\/cis559","article-title":"Summary of ceftaroline fosamil clinical trial studies and clinical safety","volume":"55","author":"File","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaip.2016.03.008_bib3","first-page":"29","article-title":"Methicillin-resistant Staphylococcus aureus nosocomial pneumonia patients treated with ceftaroline: retrospective case series of 10 patients","volume":"27","author":"Pasquale","year":"2015","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.jaip.2016.03.008_bib4","author":"Teflaro [package insert]","year":"2010"},{"key":"10.1016\/j.jaip.2016.03.008_bib5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.diagmicrobio.2014.11.016","article-title":"Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA","volume":"81","author":"Stryjewski","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jaip.2016.03.008_bib6","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1128\/AAC.02371-13","article-title":"Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy","volume":"58","author":"Casapao","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jaip.2016.03.008_bib7","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1365-2125.2010.03774.x","article-title":"Epidemiology and risk factors for drug allergy","volume":"71","author":"Thong","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2016.03.008_bib8","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/ajhp\/58.14.1317","article-title":"Potential risks and prevention, part 1: fatal adverse drug events","volume":"58","author":"Kelly","year":"2001","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jaip.2016.03.008_bib9","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra993637","article-title":"Cephalosporin allergy","volume":"345","author":"Kelkar","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2016.03.008_bib10","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jaci.2014.07.062","article-title":"Adverse reactions associated with oral and parenteral use of cephalosporins: a retrospective population-based analysis","volume":"135","author":"Macy","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2016.03.008_bib11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.anai.2010.08.002","article-title":"Drug allergy: an updated practice parameter","volume":"105","author":"Weiss","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2016.03.008_bib12","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/jac\/dkq254","article-title":"CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Corey","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jaip.2016.03.008_bib13","doi-asserted-by":"crossref","first-page":"iv53","DOI":"10.1093\/jac\/dkq255","article-title":"CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Wilcox","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jaip.2016.03.008_bib14","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/jac\/dkr096","article-title":"FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jaip.2016.03.008_bib15","doi-asserted-by":"crossref","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"Low","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jaip.2016.03.008_bib16","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2146\/ajhp130441","article-title":"Eosinophilic pneumonia induced by ceftaroline","volume":"71","author":"Griffiths","year":"2014","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jaip.2016.03.008_bib17","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/jcpt.12062","article-title":"Ceftaroline\u2013a cause for neutropenia","volume":"38","author":"Rimawi","year":"2013","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.jaip.2016.03.008_bib18","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/MAJ.0000000000000323","article-title":"Allergic interstitial nephritis due to ceftaroline","volume":"348","author":"Sulaiman","year":"2014","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jaip.2016.03.008_bib19","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.2146\/ajhp130474","article-title":"A\u00a0case of profound neutropenia and agranulocytosis associated with off-label use of ceftaroline","volume":"71","author":"Yam","year":"2014","journal-title":"Am J Health-System Pharm"},{"key":"10.1016\/j.jaip.2016.03.008_bib20","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2146\/ajhp140151","article-title":"Desensitization to ceftaroline in a patient with multiple medication hypersensitivity reactions","volume":"72","author":"Jones","year":"2015","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jaip.2016.03.008_bib21","first-page":"488","article-title":"Does prolonged ceftaroline therapy frequently cause neutropenia?","volume":"44","author":"Valour","year":"2014","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.jaip.2016.03.008_bib22","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/phar.1435","article-title":"High incidence of discontinuations due to adverse events in patients treated with ceftaroline","volume":"34","author":"Jain","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jaip.2016.03.008_bib23","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.anai.2015.05.011","article-title":"Impact of a clinical guideline for prescribing antibiotics to inpatients reporting penicillin or cephalosporin allergy","author":"Blumenthal","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2016.03.008_bib24","first-page":"376","article-title":"Creating an enterprise-wide allergy repository at Partners HealthCare System","author":"Kuperman","year":"2003","journal-title":"AMIA Annu Symp Proc"},{"key":"10.1016\/j.jaip.2016.03.008_bib25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1034\/j.1398-9995.57.s72.18.x","article-title":"Immediate hypersensitivity to cephalosporins","volume":"57","author":"Romano","year":"2002","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2016.03.008_bib26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.anai.2011.11.006","article-title":"Multiple drug intolerance syndrome: prevalence, clinical characteristics, and management","volume":"108","author":"Macy","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2016.03.008_bib27","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ijantimicag.2012.12.012","article-title":"Linezolid versus vancomycin for methicillin-resistant Staphylococcus aureus infection: a meta-analysis of randomised controlled trials","volume":"41","author":"An","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jaip.2016.03.008_bib28","doi-asserted-by":"crossref","first-page":"ofv027","DOI":"10.1093\/ofid\/ofv027","article-title":"Ceftaroline desensitization procedure in a pregnant patient with multiple drug allergies","volume":"2","author":"Kuhlen","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jaip.2016.03.008_bib29","first-page":"1534","article-title":"Sensitivity and specificity of three methods of detecting adverse drug reactions","volume":"45","author":"Berry","year":"1988","journal-title":"Am J Hosp Pharm"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219816300174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219816300174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:12:09Z","timestamp":1761973929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219816300174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S2213219816300174"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2016.03.008","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse Drug Reactions Associated with Ceftaroline Use: A 2-Center Retrospective Cohort","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2016.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}